"The U.S. Food and Drug Administration today expanded the approved use of Stivarga (regorafenib) to treat patients with advanced gastrointestinal stromal tumors (GIST) that cannot be surgically removed and no longer respond to other FDA-approved t"...
- Patient Information:
Details with Side Effects
The following serious adverse reactions are discussed in greater detail in other sections of the prescribing information:
- Anaphylaxis [see Boxed Warning, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS]
- Hemolysis [see Boxed Warning, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS]
- Methemoglobinemia [see Boxed Warning, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS]
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The data below reflect exposure to Elitek (rasburicase) in 265 pediatric and 82 adult patients enrolled in one active-controlled trial (Study 1), two uncontrolled trials (Studies 2 and 3), and an uncontrolled safety trial (n=82). Additional data were obtained from an expanded access program of 356 patients, for whom data collection was limited to serious adverse reactions. Among these 703 patients 63% were male, the median age was 10 years (range 10 days to 88 years), 73% were Caucasian, 9% African, 4% Asian, and 14% other/unknown.
Among the 347 patients for whom all adverse reactions regardless of severity were assessed, the most frequently observed adverse reactions (incidence ≥ 10%) were vomiting (50%), fever (46%), nausea (27%), headache (26%), abdominal pain (20%), constipation (20%), diarrhea (20%), mucositis (15%), and rash (13%). In Study 1, an active control study, the following adverse reactions occurred more frequently in Elitek (rasburicase) -treated subjects than allopurinol-treated subjects: vomiting, fever, nausea, diarrhea, and headache. Although the incidence of rash was similar in the two arms, severe rash was reported only in one Elitek (rasburicase) -treated patient.
Further studies, including one-active controlled study (Study 4) and four supportive studies, have been conducted in adult patients. In these studies, Elitek (rasburicase) was administered to a total of 434 adult patients [58% male, 42% female; median age 56 years (range 18 years to 89 years); 52% Caucasian, 7% African, 14% Asian, 28% other/unknown].
Of these 434 patients, 275 adult patients with leukemia, lymphoma, or solid tumor malignancies at risk for hyperuricemia and tumor lysis syndrome (TLS) were randomized in an open label trial receiving either Elitek (rasburicase) alone, Elitek (rasburicase) in combination with allopurinol, or allopurinol alone (Study 4).
A drug-related adverse reaction in Study 4 of any grade was experienced in 4.3% of Elitek (rasburicase) -treated patients, 5.4% of Elitek (rasburicase) /allopurinol-treated patients, and 1.1% of allopurinol-treated patients.
Table 1 presents the per patient incidence of adverse reactions by study arm in Study 4.
Table 1 – per patient incidence of selected adverse reactions
by study arm in Study 4
|Adverse Reaction*|| Elitek
|All Grades %||Grades 3,4 %||All Grades %||Grades 3,4 %||All Grades %||Grades 3,4 %|
|Increased alanine aminotransferase||10.9||3.3||27.2||4.3||17.6||2.2|
|*Events were reported and graded according to NCI-CTC version
3.0 and presented as preferred terms MedDRA version 10.1.
*Overall incidence ≥ 10% in any Elitek (rasburicase) arm and the difference between any Elitek (rasburicase) arm versus the allopurinol arm ≥ 5%.
Hypersensitivity reactions occurred in 4.3% of Elitek (rasburicase) -treated patients and 1.1% of Elitek (rasburicase) /allopurinol-treated patients in Study 4. Clinical manifestations of hypersensitivity included arthralgia, injection site irritation, peripheral edema, and rash.
The following serious adverse reactions occurred at a difference in incidence of ≥ 2% in patients receiving rasburicase compared to patients receiving allopurinol in randomized studies (Study 1 and Study 4): pulmonary hemorrhage, respiratory failure, supraventricular arrhythmias, ischemic coronary artery disorders, and abdominal and gastrointestinal infections.
The incidence of anaphylaxis, hemolysis, and methemoglobinemia was less than 1% of the 887 rasburicase-treated patients entered on these clinical trials.
As with all therapeutic proteins, there is potential for immunogenicity. Elitek (rasburicase) can elicit anti-product antibodies that bind to rasburicase and in some instances inhibit the activity of rasburicase in vitro [see Boxed Warning, WARNINGS AND PRECAUTIONS].
In clinical trials of pediatric patients with hematologic malignancies, 24/218 patients tested (11%) developed antibodies by day 28 following Elitek (rasburicase) administration as assessed by qualitative ELISA.
Using quasi-quantitative immunoassays in rasburicase na´ve adult patients with hematological malignancies, 47/260 (18%) patients were positive for anti-rasburicase immunoglobulin G (IgG), 21/260 (8%) patients were positive for anti-rasburicase neutralizing IgG, and 16/260 (6%) patients were positive for anti-rasburicase immunoglobulin E (IgE) from day 14 to 24 months after 5 daily doses of Elitek (rasburicase) .
The incidence of antibody responses detected is highly dependent on the sensitivity and specificity of the assay, which have not been fully evaluated. Additionally, the observed incidence of antibody positivity in an assay may be influenced by several factors, including serum sampling, timing and methodology, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to Elitek (rasburicase) with the incidence of antibodies to other products may be misleading.
Read the Elitek (rasburicase) Side Effects Center for a complete guide to possible side effects
No drug interaction studies have been conducted in humans.
Rasburicase does not metabolize allopurinol, cytarabine, methylprednisolone, methotrexate, 6-mercaptopurine, thioguanine, etoposide, daunorubicin, cyclophosphamide or vincristine in vitro. No metabolic-based drug interactions are therefore anticipated with these agents in patients.
In preclinical in vivo studies, rasburicase did not affect the activity of isoenzymes CYP1A, CYP2A, CYP2B, CYP2C, CYP2E, and CYP3A, suggesting no induction or inhibition potential. Clinically relevant P450-mediated drug-drug interactions are therefore not anticipated in patients treated with the recommended Elitek (rasburicase) dose and dosing schedule.
Last reviewed on RxList: 11/2/2009
This monograph has been modified to include the generic and brand name in many instances.
Additional Elitek Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.